ThromboGenics Ltd. Successfully Completes Private Share Offering Raising EUR23.9 Million

LEUVEN, Belgium, May 9 /PRNewswire/ -- ThromboGenics NV , a biotechnology company focused on vascular disease, announces that it has raised EUR23.9 million through a private placement of 2,214,030 new shares. In conjunction with this transaction existing shareholders Biggar Limited and three small individual shareholders sold 2,952,487 shares.

The private placement announced this morning has allowed ThromboGenics to place 2,214,030 new shares (approximately 10% of the outstanding shares) with institutional investors at a price of EUR10.80 per share. The new shares are expected to be issued on 14 May 2007. ThromboGenics will apply for admission of the new shares on Eurolist by Euronext Brussels.

ThromboGenics was further informed that, subject to the settlement of the capital increase, Biggar Limited along with three small individual shareholders sold 2,952,487 existing shares at the same price.

The demand for the combined offering of shares was more then 1.5 times the available number of shares due to interest from a large number of high quality Belgian and international investors.

KBC Securities acted as lead manager and was assisted by Kempen & Co.

Commenting on today's announcement, Prof. Desire Collen, CEO of ThromboGenics, said: "I am very pleased that we have been able to secure this additional funding from a broad range of institutional investors, significantly reinforcing our financial position. These new funds will enable us to advance the development of our product portfolio including our lead product, microplasmin, which is currently being evaluated in several Phase II clinical trials in eye disorders and vascular occlusive diseases. In addition, the placement of shares by certain of the Company's pre-IPO investors should lead to improved liquidity in our shares, an important consideration for all of our shareholders."

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics also has one program, TB-402 (Anti-Factor VIII), in Phase I clinical trials, and three other drug candidates in preclinical development with preclinical proof-of-principle demonstrated. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin,Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.

CONTACT: For further information please contact: ThromboGenics: Prof.Desire Collen, CEO, Chris Buyse, CFO, Tel: +32-(0)-16-34-61-94; CitigateDewe Rogerson: David Dible / Valerie Auffray, Tel: +44-(0)-207-638-95-71